Disruption of nasal bacteria enhances protective immune responses to influenza A virus and SARS-CoV-2 infection in mice
Abstract
Gut microbiota plays a critical role in the induction of adaptive immune responses to influenza virus infection. However, the role of nasal bacteria in the induction of the virus-specific adaptive immunity is less clear. Here we demonstrate that while intranasal administration of influenza virus hemagglutinin vaccine alone was insufficient to induce the vaccine-specific antibody responses, disruption of nasal bacteria by lysozyme or addition of culturable oral bacteria from a healthy human volunteer rescued inability of the nasal bacteria to generate antibody responses to intranasally administered the split-virus vaccine. Myd88-depdnent signaling in the hematopoietic compartment was required for adjuvant activity of intranasally administered oral bacteria. In addition, we found that the oral bacteria-combined intranasal vaccine induced protective antibody response to influenza virus and SARS-CoV-2 infection. Our findings here have identified a previously unappreciated role for nasal bacteria in the induction of the virus-specific adaptive immune responses.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Immunogenicity and protective efficacy of an intranasal neuraminidase-based influenza virus vaccine adjuvanted with bacterial cell membrane-derived adjuvants
Kirill Vasilev, Irene Hoxie, … Florian Krammer·bioRxiv·Feb 26, 2025
- Intranasal administration of split-inactivated influenza virus vaccine mixed with a novel adjuvant elicits protective antibodies against seasonal influenza viruses.
Michael A. Carlock, Katherine Lynn Cupo, Ted M. Ross·bioRxiv·Oct 23, 2025
- Intranasal hemagglutinin protein boosters induce robust mucosal immunity and cross-protection against influenza A viral challenge
Miyu Moriyama, Gisele Regina Rodrigues, … Akiko Iwasaki·Proceedings of the National Academy of SciencesPeer-reviewed·Sep 24, 2025
- Oral immunization with rVSV bivalent vaccine elicits protective immune responses, including ADCC, against both SARS-CoV-2 and Influenza A viruses
M. J. Ouyang, Z. Ao, … X. Yao·bioRxiv·Jul 14, 2023
- Influenza A Virus Exacerbates Group A Streptococcus Infection and Thwarts Anti-bacterial Inflammatory Responses in Murine Macrophages
J. Aleith, M. Brendel, … B. Müller-Hilke·bioRxiv·Mar 10, 2022
- Prophylactic protection against respiratory viruses conferred by a prototype live attenuated influenza virus vaccine.
R. Rathnasinghe, M. Salvatore, … A. Garcia-Sastre·bioRxiv·Apr 28, 2021